A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Official title

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Overview

This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.

Interventions

• Drug BL-M07D1
  Administration by intravenous infusion

Primary outcome measures

• Phase Ib: Recommended Phase II Dose (RP2D) [Time frame: Up to 21 days after the first dose]
• Phase II: Objective Response Rate (ORR) [Time frame: Up to approximately 24 months]

Secondary outcome measures (9)

• Treatment-Emergent Adverse Event (TEAE) [Time frame: Up to approximately 24 months]
• Phase Ib: Objective Response Rate (ORR) [Time frame: Up to approximately 24 months]
• Disease Control Rate (DCR) [Time frame: Up to approximately 24 months]
• Duration of Response (DOR) [Time frame: Up to approximately 24 months]
• Progression-free Survival (PFS) [Time frame: Up to approximately 24 months]
• Cmax [Time frame: Up to 21 days after the first dose]
• Tmax [Time frame: Up to 21 days after the first dose]
• Ctrough [Time frame: Up to 21 days after the first dose]
• ADA (anti-drug antibody) [Time frame: Up to approximately 24 months]

Eligibility criteria

Inclusion criteria

• Voluntarily sign the informed consent and follow the requirements of the protocol.
• No gender limit.
• Age: ≥18 years old and ≤75 years old.
• expected survival time ≥3 months.
• Histologically or cytologically confirmed, unresectable locally advanced or metastatic non-small cell lung cancer.
• Confirmed known HER2-sensitive mutations, investigator-confirmed previous testing results, and trial site laboratory testing results were acceptable.
• Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment.
• Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing; Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and exclusion criteria after evaluation by investigators.
• Must have at least one measurable lesion according to RECIST v1.1 definition.
• ECOG score 0 or 1.
• Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
• No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.
• Organ function levels must meet the requirements.
• Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.
• Urine protein ≤2+ or ≤1000mg/24h.
• For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion criteria

• Received chemotherapy, biological therapy, immunotherapy or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.).
• Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin.
• Presence of other gene mutations for targeted drug therapy.
• A history of severe cardiovascular and cerebrovascular diseases.
• Active autoimmune or inflammatory diseases.
• Patients with other malignant tumors within 5 years before the first administration.
• Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.
• Patients with poorly controlled pericardial effusion, pleural effusion, peritoneal effusion, or pelvic effusion with clinical symptoms were judged by the investigator to be ineligible for enrollment.
• Hypertension poorly controlled by antihypertensive drugs (systolic BP \> 150 mmHg or diastolic blood pressure \> 100 mmHg).
• Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases.
• Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). .
• Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D1.
• Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
• Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > lower detection limit).
• Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.
• Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose).
• Pregnant or lactating women.
• Other circumstances considered by the investigator to be inappropriate for participation in the trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Sun Yat-sen University Cancer Center — Guangzhou

Identifiers

NCT: NCT06114511 · BL-M07D1-201

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗